• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用世卫组织全球基准工具加强公共卫生突发事件临床试验监督能力:GHPP VaccTrain 模式。

Leveraging WHO's Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model.

机构信息

Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Unit G3: International Coordination/Regulatory Services, Paul-Ehrlich Str. 51-59, 63225, Langen, Germany.

Paul-Ehrlich-Institut, Global Health Protection Programme (GHPP) RegTrain-VaccTrain, Langen, Germany.

出版信息

Global Health. 2022 Jun 20;18(1):63. doi: 10.1186/s12992-022-00854-0.

DOI:10.1186/s12992-022-00854-0
PMID:35725614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9207864/
Abstract

BACKGROUND

A stable, well-functioning and integrated national medicines regulatory system is a core component of health systems resilient against infectious disease outbreaks. In many low- and middle-income countries, however, sizable gaps exist in the emergency preparedness framework of national regulatory authorities (NRAs). RegTrain-VaccTrain is a project of Germany Ministry of Health's Global Health Protection Programme that contributes to global efforts aimed at strengthening such regulatory systems by providing technical support and advice to partner NRAs. In this study, we probed the outputs of our capacity-strengthening activities for clinical trials oversight (CTO) to take stock of progress made and examine remaining priorities in order to provide specialized technical assistance in addressing them to improve operational readiness for emergencies.

METHOD

Data validated from NRA self-benchmarking results in 2017 and worksheet records of November 2021 were utilized to assess the emergency preparedness capacity for CTO in three VaccTrain partner NRAs (Liberia, Sierra Leone, The Gambia) before and after interventional capacity-strengthening partnership, using specific public health emergency-related (sub-)indicators of the WHO Global Benchmarking Tool.

RESULTS

A generally weak and vulnerable structural framework for CTO characterized the emergency preparedness capacity in all three partner NRAs at baseline, thus putting their operational readiness for public health emergencies at risk. VaccTrain's collaborative work was successful at supporting individual NRAs to develop the full spectrum of operational structures (including (draft) regulations, guidelines, and standard operating procedures) required to improve regulatory preparedness. A gap in the formal approval and implementation of developed legal documents in two of three NRAs still remains. Notwithstanding, a robust emergency framework now exists and the NRAs stand better prepared to respond to (future) locally-concerning health emergencies, during which time clinical trials activity was observed to heighten.

CONCLUSIONS

These results exemplify a north-south capacity-strengthening partnership model that effectively contributes in developing structures to enhance regulatory oversight and support expeditious product development in response to crises. They further underscore the equally critical role local/national processes play in facilitating the full implementation of developed structures.

摘要

背景

一个稳定、运作良好且整合的国家药品监管体系是应对传染病疫情的卫生系统的核心组成部分。然而,在许多中低收入国家,国家监管机构(NRA)的应急准备框架仍存在较大差距。RegTrain-VaccTrain 是德国卫生部全球卫生保护计划的一个项目,通过向合作伙伴 NRA 提供技术支持和建议,为加强此类监管系统的全球努力做出贡献。在这项研究中,我们探讨了我们加强临床试验监督(CTO)能力建设活动的产出,以评估进展情况并检查剩余的优先事项,以便提供专门的技术援助来解决这些问题,提高应对紧急情况的运作准备。

方法

利用 NRA 2017 年自我基准测试结果和 2021 年 11 月工作表记录的数据进行验证,使用世卫组织全球基准工具的特定与公共卫生应急相关的(分)指标,在干预前和干预后评估三个 VaccTrain 合作伙伴 NRA(利比里亚、塞拉利昂、冈比亚)的 CTO 应急准备能力。

结果

在基线时,所有三个合作伙伴 NRA 的 CTO 应急准备能力都表现出结构框架薄弱和脆弱的特点,这使其应对公共卫生紧急情况的运作准备处于风险之中。VaccTrain 的合作工作成功地支持了各个 NRA 发展改进监管准备所需的全方位运作结构(包括(草案)法规、准则和标准作业程序)。在三个 NRA 中的两个中,仍存在制定的法律文件正式批准和实施方面的差距。尽管如此,现在已经建立了一个强大的应急框架,NRA 更有能力应对(未来)当地关注的卫生紧急情况,在此期间观察到临床试验活动有所增加。

结论

这些结果例证了南北合作的能力建设伙伴关系模式,有效地为加强监管监督和支持快速产品开发应对危机提供了结构。它们进一步强调了地方/国家进程在促进充分实施制定的结构方面同样至关重要的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/b58680dceae9/12992_2022_854_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/820bc207f923/12992_2022_854_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/287b0815f192/12992_2022_854_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/b58680dceae9/12992_2022_854_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/820bc207f923/12992_2022_854_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/287b0815f192/12992_2022_854_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9208113/b58680dceae9/12992_2022_854_Fig3_HTML.jpg

相似文献

1
Leveraging WHO's Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model.利用世卫组织全球基准工具加强公共卫生突发事件临床试验监督能力:GHPP VaccTrain 模式。
Global Health. 2022 Jun 20;18(1):63. doi: 10.1186/s12992-022-00854-0.
2
Worldwide Assessment of Low- and Middle-Income Countries' Regulatory Preparedness to Approve Medical Products During Public Health Emergencies.中低收入国家在突发公共卫生事件期间批准医疗产品的监管准备情况的全球评估。
Front Med (Lausanne). 2021 Aug 13;8:722872. doi: 10.3389/fmed.2021.722872. eCollection 2021.
3
Quantitative analysis of International Health Regulations Annual Reports to identify global disparities in the preparedness for radiation emergencies.对《国际卫生条例》年度报告进行定量分析,以确定全球在辐射突发事件准备方面的差距。
BMJ Open. 2022 Sep 5;12(9):e052670. doi: 10.1136/bmjopen-2021-052670.
4
The Pivotal Role of Quality Technical Structures for Clinical Trials Oversight in the Achievement of Long-Term Capacity Strengthening Outcomes.质量技术结构在临床试验监督中对实现长期能力加强成果的关键作用。
Front Med (Lausanne). 2022 Mar 2;9:772605. doi: 10.3389/fmed.2022.772605. eCollection 2022.
5
What is public health legal preparedness?什么是公共卫生法律准备?
J Law Med Ethics. 2003 Winter;31(4):672-83. doi: 10.1111/j.1748-720x.2003.tb00134.x.
6
The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity.世卫组织全球基准工具:加强国家监管能力的游戏规则改变者。
BMJ Glob Health. 2020 Aug;5(8). doi: 10.1136/bmjgh-2020-003181.
7
Multisectoral action towards sustainable development goal 3.d and building health systems resilience during and beyond COVID-19: Findings from an INTOSAI development initiative and World Health Organization collaboration.多部门行动以实现可持续发展目标 3.d 并在 COVID-19 期间和之后增强卫生系统的弹性:来自国际审计组织发展倡议和世界卫生组织合作的发现。
Front Public Health. 2023 May 19;11:1104669. doi: 10.3389/fpubh.2023.1104669. eCollection 2023.
8
The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage.世界卫生组织全球基准工具:加强医疗产品监管和促进全民健康覆盖的工具
Front Med (Lausanne). 2020 Aug 19;7:457. doi: 10.3389/fmed.2020.00457. eCollection 2020.
9
Establishing National Multisectoral Coordination and collaboration mechanisms to prevent, detect, and respond to public health threats in Guinea, Liberia, and Sierra Leone 2016-2018.2016 - 2018年在几内亚、利比里亚和塞拉利昂建立国家多部门协调与合作机制,以预防、发现并应对公共卫生威胁。
One Health Outlook. 2019 Nov 27;1:4. doi: 10.1186/s42522-019-0004-z. eCollection 2019.
10
Learning interventions in the WHO Eastern Mediterranean region: supporting Member States to get prepared for better response to health emergencies in the region.世界卫生组织东地中海区域的学习干预措施:支持成员国做好准备,以更好地应对该区域的卫生突发事件。
Front Public Health. 2024 Sep 12;12:1441223. doi: 10.3389/fpubh.2024.1441223. eCollection 2024.

引用本文的文献

1
PEARLES challenges and solutions to the implementation of clinical research responses to epidemics and pandemics: a scoping review.PEARLES:应对流行病和大流行的临床研究实施中的挑战与解决方案:一项范围综述
EClinicalMedicine. 2025 Jun 27;85:103294. doi: 10.1016/j.eclinm.2025.103294. eCollection 2025 Jul.
2
Capacity Assessment of the National Medicines Regulatory Authority in a Low -Income Country.国家药品监督管理局在低收入国家的能力评估。
Ther Innov Regul Sci. 2024 Nov;58(6):1053-1060. doi: 10.1007/s43441-024-00683-w. Epub 2024 Aug 4.
3
Benchmarking Drug Regulatory Systems for Capacity Building: An Integrative Review of Tools, Practice, and Recommendations.

本文引用的文献

1
The Pivotal Role of Quality Technical Structures for Clinical Trials Oversight in the Achievement of Long-Term Capacity Strengthening Outcomes.质量技术结构在临床试验监督中对实现长期能力加强成果的关键作用。
Front Med (Lausanne). 2022 Mar 2;9:772605. doi: 10.3389/fmed.2022.772605. eCollection 2022.
2
Worldwide Assessment of Low- and Middle-Income Countries' Regulatory Preparedness to Approve Medical Products During Public Health Emergencies.中低收入国家在突发公共卫生事件期间批准医疗产品的监管准备情况的全球评估。
Front Med (Lausanne). 2021 Aug 13;8:722872. doi: 10.3389/fmed.2021.722872. eCollection 2021.
3
药物监管系统能力建设的基准测试:工具、实践和建议的综合回顾。
Int J Health Policy Manag. 2023;12:8100. doi: 10.34172/ijhpm.2023.8100. Epub 2023 Oct 16.
Strengthening capacity for clinical research in sub-Saharan Africa: partnerships and networks.
加强撒哈拉以南非洲的临床研究能力:伙伴关系和网络。
Int J Infect Dis. 2021 Sep;110:54-61. doi: 10.1016/j.ijid.2021.06.061. Epub 2021 Jul 1.
4
Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic.2019年冠状病毒病大流行期间与临床试验研究相关的障碍和考量因素
Front Med (Lausanne). 2020 Dec 23;7:598038. doi: 10.3389/fmed.2020.598038. eCollection 2020.
5
The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage.世界卫生组织全球基准工具:加强医疗产品监管和促进全民健康覆盖的工具
Front Med (Lausanne). 2020 Aug 19;7:457. doi: 10.3389/fmed.2020.00457. eCollection 2020.
6
Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review.应对新发传染病和大流行的临床研究应对挑战:范围综述。
BMC Med. 2020 Jun 25;18(1):190. doi: 10.1186/s12916-020-01624-8.
7
Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.将埃博拉疫苗经验教训应用于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其他流行病原体。
NPJ Vaccines. 2020 Jun 15;5(1):51. doi: 10.1038/s41541-020-0204-7. eCollection 2020.
8
Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?COVID-19 临床试验:我们能否更好地利用短暂的机会窗口?
Clin Pharmacol Ther. 2020 Oct;108(4):730-733. doi: 10.1002/cpt.1891. Epub 2020 Jun 12.
9
Description of vaccine clinical trials in Africa: a narrative review.非洲疫苗临床试验描述:叙事性综述。
Hum Vaccin Immunother. 2020 Apr 2;16(4):972-980. doi: 10.1080/21645515.2019.1693720. Epub 2019 Dec 12.
10
Training through malaria research: building capacity in good clinical and laboratory practice in Liberia.通过疟疾研究进行培训:在利比里亚建立良好临床和实验室实践能力。
Malar J. 2019 Apr 17;18(1):136. doi: 10.1186/s12936-019-2767-1.